[Clinical study on netilmicin in the treatment of complicated urinary tract infection caused by Pseudomonas aeruginosa].
Netilmicin was intramuscularly injected at a daily dose of 200 mg, divided twice, for 5 to 10 days to 14 patients with complicated urinary tract infection caused by P. aeruginosa. The clinical results were excellent in 7 cases, good in 5 cases, and fair in 2 cases. Neither side effects nor abnormal values in laboratory findings were reported. The MIC of netilmicin against 14 strains of P. aeruginosa isolated from the above patients were distributed between 3.13 micrograms/ml and 12.5 micrograms/ml except 1 strain at inoculum size 10(6) cells/ml.
D000368:Aged; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D005839:Gentamicins; D009428:Netilmicin